سعر Rosuvastatin 10 mg film-coated tablets (Borg), 14 tablets 2024

Rosuvastatin 10 mg film-coated tablets, listed by Egyptian price directories under Borg; HMG-CoA reductase inhibitor (statin); box of 14 film-coated tablets.

• To reduce the risk of major adverse cardiovascular events in adults at increased risk.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolaemia, to slow progression of atherosclerosis, and in paediatric HeFH (8 years and older) and HoFH (7 years and older).Population: Adults and paediatric patients with HeFH/HoFHDailyMed (U.S. National Library of Medicine)
• Adjunct to diet in adults with primary dysbetalipoproteinaemia or hypertriglyceridaemia.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most frequent adverse reactions (2% or more): headache, nausea, myalgia, asthenia and constipation.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Acute liver failure or decompensated cirrhosis.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to rosuvastatin or any excipient (rash, pruritus, urticaria and angioedema have been reported).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Myopathy and rhabdomyolysis (with rare acute kidney injury and fatalities); risk factors include age 65 years or older, uncontrolled hypothyroidism, renal impairment, certain concomitant drugs and higher doses. Discontinue if CK is markedly elevated or myopathy is diagnosed or suspected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Immune-mediated necrotising myopathy (IMNM) has been reported rarely with statins; discontinue if suspected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hepatic dysfunction: transaminase increases, and rare fatal and non-fatal hepatic failure; consider liver enzyme testing before starting and as clinically indicated, and discontinue promptly if serious hepatic injury occurs.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• CyclosporineIncreases rosuvastatin exposure about 7-fold; do not exceed 5 mg once daily.DailyMed (U.S. National Library of Medicine)
• GemfibrozilAvoid concomitant use; if unavoidable, start at 5 mg once daily and do not exceed 10 mg once daily (increased myopathy risk).DailyMed (U.S. National Library of Medicine)
• DarolutamideIncreases rosuvastatin exposure more than 5-fold; do not exceed 5 mg once daily.DailyMed (U.S. National Library of Medicine)

• Discontinue when pregnancy is recognised, or consider the ongoing therapeutic needs of the individual patient. May cause fetal harm based on its mechanism of action.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Limited case data show rosuvastatin in human milk; breastfeeding is not recommended during treatment.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Rosuvastatin: Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate (a cholesterol precursor); this increases hepatic LDL-receptor expression and lowers plasma LDL-C.